KRAS cell membrane dynamic and novel anticancer strategies
The RAS/MAPK pathway integrates signals from a diverse range of stimuli to control cellular homeostasis. It is frequently deregulated in human diseases, including cancer. The GTPase KRAS is part of the RAS/MAPK pathway, and its mutations are implicated in oncogenesis. The overarching goal of the EU-funded KARMA project is the characterisation in vitro and in vivo of the KRAS protein complex and its function concerning human diseases. The project will capitalise on the researcher's discovery that dimerization drives the function of oncogenic KRAS. During the project, the tumour suppressor effect of wild-type KRAS protomers in oncogenic KRAS-driven complexes will be studied, and the therapeutic impact of the complex disruption will be determined.
Fields of science
Funding SchemeERC-COG - Consolidator Grant
See on map